Management Strategies for Status Epilepticus

Status epilepticus denotes a neurologic emergency characterised by continuous or rapidly recurring seizures without recovery of consciousness, typically lasting longer than five minutes. The cornerstone of initial management is prompt administration of benzodiazepines to enhance GABAergic inhibition. If seizures persist beyond first-line therapy, second-line agents such as fosphenytoin, valproate or levetiracetam are introduced to stabilise neuronal membranes and modulate ion channels. In cases where conventional antiepileptic drugs fail—termed refractory status epilepticus—anaesthetic infusions of midazolam, propofol or thiopental are employed in intensive care settings, with EEG monitoring guiding depth of sedation and propensity for burst suppression. For super-refractory status epilepticus, defined by ongoing seizure activity despite 24 hours of anaesthetic treatment, adjunctive strategies include NMDA receptor antagonists (notably ketamine), immunotherapies in suspected autoimmune aetiologies, ketogenic dietary regimens and, in select centres, intermittent stimulation techniques such as electroconvulsive therapy. Across all stages, careful attention to airway protection, haemodynamic support and correction of metabolic disturbances underpins neuroprotective care. Emerging approaches focus on precision medicine, including biomarker-driven immunomodulation and novel small-molecule compounds that target glutamatergic and inflammatory pathways, with the aim of reducing long-term morbidity and mortality on a global scale.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Management Strategies for Status Epilepticus publication trend

The graph below shows the total number of articles in management strategies for status epilepticus across all publications each year (not limited to Nature Index journals).

Technical terms

Status epilepticus (SE): A continuous seizure or series of seizures lasting more than five minutes without recovery of consciousness.

Refractory status epilepticus (RSE): Seizures that do not respond to first-line benzodiazepines and a second-line antiepileptic drug.

Super-refractory status epilepticus (SRSE): Ongoing seizures despite 24 hours of general anaesthetic infusion.

NMDA receptor antagonist: A compound that inhibits N-methyl-D-aspartate receptors to reduce excitatory neurotransmission.

Burst suppression: An EEG pattern induced by anaesthetic agents to prevent seizure activity through alternating high-voltage bursts and electrical quiescence.

References

1. Insight into Drug Resistance in Status Epilepticus: Evidence from Animal Models. International Journal of Molecular Sciences (2023).
2. The efficacy and safety of ketamine in the treatment of super-refractory status epilepticus: a systematic review. Journal of Neurology (2024).
3. Use of ketamine in Super Refractory Status Epilepticus: a systematic review. Neurological Research and Practice (2024).
4. Super-refractory status epilepticus and ketogenic diet in intensive care: a series report. Revista Brasileira de Terapia Intensiva (2021).
5. Treatment of status epilepticus: Physiology, pharmacology, and future directions. Epilepsia Open (2023).